DPHARMA 7148
FAIRLY VALUED

DPHARMA 7148

RM3.10

(7 customer reviews)
52 Weeks Range : 1.05 - 4.32

5 day volume Average = 12,238,020
20 day volume Average = 28,086,405
90 day volume Average = 16,296,938
Add to wishlistAdded to wishlistRemoved from wishlist 3
Add to compare
4.6/10 (Expert Score)
Stock is rated as #1 in category Biotechnology
Fairly Valued. Reach or higher than intrinsic value.
PROS:
  • Small Dividend Payout
  • Very High Trading Value
CONS:
  • Poor Income Near Future
  • Very Low Price-to-Tangible
  • High Gearing Ratio

klse: Duopharma Biotech Bhd


Corporate Information

Board   : Main

Shariah : Shariah Compliant

Sector   : Biotechnology Ringgit Consumer Healthcare

Address: Suite 18.06, Level 18, Kenanga International, No. 26, Jalan Sultan Ismail, 50250, Kuala Lumpur

Contact: +603-21620218

Website: https://www.duopharmabiotech.com/
 

Corporate Background

Duopharma Biotech Berhad operates as an investment holding company. The Company, through its subsidiaries, invests in the pharmaceutical and healthcare sectors. Duopharma Biotech serves customers in Malaysia.

Forecast: DPHARMA 7148

Market Capital (RM) 2, 188, 683, 446
Forecasted Profit or Loss (RM) 63, 339, 643
Estimated Future EPS (sen) 8.971
Perspective P/E ratio 34.555
Estimated Dividend Yield (%) 1.884
Adjusted NTA (RM) 0.82

Result

Quarter Report History

Date Revenue,k PBT,k Net Profit,k
13/08/20 143,331 19,391 14,729
18/05/20 158,713 17,727 13,561
13/02/20 137,755 13,939 12,033
29/11/19 142,855 19,768 14,859
30/08/19 145,466 18,316 13,916
21/05/19 150,386 18,786 14,465
18/02/19 115,634 17,658 14,369
28/11/18 125,838 15,838 12,286
26/11/18 123,991 12,915 10,339
28/05/18 133,259 13,255 10,782
28/02/18 112,253 12,825 11,870
17/11/17 115,379 14,207 11,405

Fundamental

Fundamental Analysis

Last 4 Quarter Revenue (RM’000) 582,654
Last 4 Quarter Net Profit (RM’000) 55,182
Last 4 Quarter EPS (sen) 8.09
Last 4 Quarter PER 39.66
Last 4 Quarter Dividend (sen) 5.50
Last 4 Quarter Dividend Yield (%) 1.77
Net Tangible Assets (RM) 0.77
Goodwill (RM) 30,000
Cash (RM’000) 163,670
Debt (RM’000) 277,130
Total Debt (RM’000) 423,390
Net Assets (RM’000) 583,940
Current Ratio 1.74
Quick Ratio 1.14
Cash Ratio 0.50

Technical

Technical Analysis

MACD (26 vs 12) 0.064
Exponential Moving Average 5 3.178
Exponential Moving Average 20 3.159
Exponential Moving Average 90 2.506
Relative Strength Index 14 0.41
Stochastic %D 3 0.52
Stochastic %K 14 0.58

7 reviews for DPHARMA 7148

3.2 out of 5
0
2
3
1
0
Write a review
Show all Most Helpful Highest Rating Lowest Rating
  1. Avatar

    BURSA MALAYSIA

    The Group has recorded a lower revenue of RM 143.33 million for the current quarter ended 30 June 2020 as compared to RM 158.71 million for the preceding financial quarter. Decrease in Group’s revenue was mainly due to lower demand from public health sector and also challenging environment faced by private clinics and hospitals during the Movement Control Order (MCO). However, the Group’s PBT increased by 9.39% to RM 19.39 million in the current quarter as compared to RM 17.73 million in the preceding financial quarter, mainly due to strengthening of US Dollar resulting in unrealised forex losses on our borrowings in USD in our loan portfolio in the preceding financial quarter.

    Helpful(0) Unhelpful(0)You have already voted this
  2. Avatar

    INVESTING MALAYSIA

    DPHARMA (18 DEC 19) Duopharma Biotech Bhd continues to have a bullish outlook for its group performance next year, leveraging the country’s higher healthcare allocation under the 2020 Budget.

    Helpful(0) Unhelpful(0)You have already voted this
  3. Avatar

    Investing Malaysia

    Average investing volume for Duopharma Biotech Bhd in the past three months in stock market was 828.9k lots

    Helpful(0) Unhelpful(0)You have already voted this
  4. Avatar

    Investing Malaysia

    DPHARMA gets a score of 12.34 in our equity and assets quality test based on current share price of RM1.63

    Helpful(0) Unhelpful(0)You have already voted this
  5. Avatar

    Investing Malaysia

    Duopharma Biotech Bhd gets a score of 22.21 in our stability test after the balance sheet, money statement study

    Helpful(0) Unhelpful(1)You have already voted this
  6. Avatar

    Investing Malaysia

    Stock code of 7148 in Bursa Malaysia declared adjusted 3.54% dividend yield in past few years

    Helpful(0) Unhelpful(0)You have already voted this
  7. Avatar

    Investing Malaysia

    DPHARMA is estimated to have a profit consensus of 64.25 millions, with an adjusted market capitalization of 1088.17 millions

    Helpful(0) Unhelpful(0)You have already voted this

    Add a review

    Your email address will not be published.

    Register New Account
    Name (required)
    Reset Password
    Compare items
    • Total (0)
    Compare